- Gus Cairns | 01 September 2017
Two presentations at the recent International AIDS Society Conference on HIV Science (IAS 2017) in
Paris told delegates that both trial results and analysis of drug levels supported the
idea that event-related, ...
- Gus Cairns | 29 August 2017
There is a lot we don’t know about trans women’s HIV
risk, why they are so vulnerable to HIV and who trans women are acquiring HIV from. A study presented
at last ...
- Gus Cairns | 28 August 2017
One in seven people (14%) offered pre-exposure prophylaxis (PrEP) in a large community study of enhanced HIV testing and treatment in Kenya and Uganda started PrEP
the day they were offered ...
- Liz Highleyman | 23 August 2017
Transgender women living with
HIV may be hesitant to use antiretroviral therapy (ART) or not take it as
prescribed because of concerns about drug interactions with feminising
hormones, according to a presentation at ...
- Liz Highleyman | 21 August 2017
Metabolic syndrome, type 2 diabetes and obesity are risk factors for the development of liver fibrosis and steatosis (liver fat accumulation) in people living with HIV, including those who do ...
- Keith Alcorn | 15 August 2017
Peripheral artery disease, one of the most common forms of cardiovascular disease, occurs more frequently in people with HIV who have CD4 cell counts below 500, regardless of whether they ...
- Liz Highleyman | 14 August 2017
An estimated 120,000 people in the US have started Truvada for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of retail and mail-order pharmacies by ...
- Keith Alcorn | 09 August 2017
Switching from a boosted protease inhibitor to the integrase inhibitor dolutegravir was associated with lipid reductions in people with HIV at higher risk of heart disease, according to results of ...
- Keith Alcorn | 08 August 2017
A combination of darunavir/ritonavir and lamivudine was just as effective as the same combination plus tenofovir, according to 24-week results of the ANDES study presented last month by Professor Pedro ...
- Gus Cairns | 03 August 2017
For the last few years, a specialist symposium on HIV cure
research has preceded the International AIDS Society (IAS) Conferences and this one was no exception, with a
1.5-day Forum at Paris’s ...
- Gus Cairns | 03 August 2017
The first part of this report from the 2017 IAS Cure and Cancer Forum, which was held in advance of the IAS 2017 conference, looked at recent developments in research ...
- Gus Cairns | 03 August 2017
What all the different approaches discussed in the previous two reports have in common is that they aim to put HIV
infection into persistent remission. But they do not
completely remove HIV ...
- Liz Highleyman | 02 August 2017
A broadly neutralising antibody modestly delayed
the resurgence of viral replication following interruption of antiretroviral therapy
(ART) started during very early infection, but all study participants
ultimately experienced viral rebound, according to results ...
- Liz Highleyman | 02 August 2017
A single oral dose of MK-8591, a long-acting antiretroviral
in a novel drug class, suppressed HIV for seven days in an early clinical
trial, and the drug also appears to protect monkeys ...
- Carole Leach-Lemens | 01 August 2017
The stillbirth rate among women living with HIV in the UK and Ireland from 2007 to 2015 was more than twice that of the general population, Graziella Favarato, presenting on ...
- Keith Alcorn | 01 August 2017
A withdrawal of United States funding for HIV treatment and prevention in sub-Saharan Africa could lead to 20 million additional HIV infections and 2 million additional AIDS deaths between now and 2032, ...
- Liz Highleyman | 01 August 2017
The first once-daily single-tablet regimen containing a protease inhibitor maintained viral suppression in almost everyone who switched after achieving undetectable HIV RNA on a multi-pill regimen, according to a report ...
- Carole Leach-Lemens | 31 July 2017
Adolescents who acquired HIV perinatally were less likely to die, grew faster and had better immune restoration on treatment if they lived in upper-middle income countries in sub-Saharan Africa, a ...
- Roger Pebody | 28 July 2017
France is launching a new study which will enrol 3000 new
pre-exposure prophylaxis (PrEP) users over the next three years, Jean-Michel Molina told the 9th International AIDS Society Conference
on HIV Science (IAS ...
- Gus Cairns | 28 July 2017
In Europe, whether through national
programmes or in trials, people are more often than not being given the choice of
taking pre-exposure prophylaxis (PrEP) daily or intermittently (“event-driven” or “on-demand” PrEP). The
French ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...